{"id":16029,"date":"2022-03-25T11:40:26","date_gmt":"2022-03-25T10:40:26","guid":{"rendered":"https:\/\/convergences.online\/hemato\/?p=16029"},"modified":"2022-03-25T11:40:26","modified_gmt":"2022-03-25T10:40:26","slug":"janssen-a-recu-un-avis-favorable-du-chmp-pour-lautorisation-de-carvykti-ciltacabtagene-autoleucel-pour-le-traitement-des-patients-atteints-dun-myelome-multiple-en-rechute-et-refractaire-apres-le","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/janssen-a-recu-un-avis-favorable-du-chmp-pour-lautorisation-de-carvykti-ciltacabtagene-autoleucel-pour-le-traitement-des-patients-atteints-dun-myelome-multiple-en-rechute-et-refractaire-apres-le\/","title":{"rendered":"Janssen a re\u00e7u un avis favorable du CHMP pour l&#8217;autorisation de CARVYKTI (ciltacabtagene autoleucel) pour le traitement des patients atteints d&#8217;un my\u00e9lome multiple en rechute et r\u00e9fractaire apr\u00e8s les 3 principales classes th\u00e9rapeutiques disponibles"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1302px;margin-left: calc(-5% \/ 2 );margin-right: calc(-5% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:2.375%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:2.375%;--awb-width-medium:100%;--awb-spacing-right-medium:2.375%;--awb-spacing-left-medium:2.375%;--awb-width-small:100%;--awb-spacing-right-small:2.375%;--awb-spacing-left-small:2.375%;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><p>L&#8217;avis favorable du CHMP est bas\u00e9 sur les donn\u00e9es de l&#8217;\u00e9tude pivot CARTITUDE-1. Les r\u00e9sultats de cette \u00e9tude ont \u00e9t\u00e9 pr\u00e9sent\u00e9s lors du congr\u00e8s annuel de l&#8217;American Society of Hematology (ASH) 2021 (abstract n\u00b0 549).2 &#8221; Chez Janssen, nous sommes r\u00e9solument engag\u00e9s \u00e0 faire progresser la science et \u00e0 am\u00e9liorer le pronostic des patients diagnostiqu\u00e9s avec un my\u00e9lome multiple &#8220;, a d\u00e9clar\u00e9 Sen Zhuang, M.D., Ph.D., vice-pr\u00e9sident de la recherche clinique en oncologie chez Janssen R&amp;D &#8211; LLC. &#8220;L&#8217;avis favorable du CHMP rendu aujourd&#8217;hui marque des progr\u00e8s importants dans le d\u00e9veloppement clinique en cours et l&#8217;enregistrement de cilta-cel, au niveau mondial.&#8221; Cet avis du CHMP fait suite \u00e0 la r\u00e9cente approbation du cilta-cel par la Food and Drug Administration (FDA) am\u00e9ricaine en f\u00e9vrier 2022.<\/p>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":17,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[21],"tags":[],"ppma_author":[457],"class_list":["post-16029","post","type-post","status-publish","format-standard","hentry","category-communique-de-presse","author-pascale-raoul"],"aioseo_notices":[],"authors":[{"term_id":457,"user_id":17,"is_guest":0,"slug":"pascale-raoul","display_name":"Pascale Raoul","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/?s=96&d=mm&r=g","first_name":"","last_name":"","user_url":"","description":""}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16029","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=16029"}],"version-history":[{"count":0,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16029\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=16029"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=16029"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=16029"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=16029"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}